IDH2 and hematologic disorder: This IDH2 inhibitor underwent Phase I and Phase II clinical trials, in which effective 2HG levels decrease was observed both in bone marrow and in plasma, achieving sustainable remission of disease in some patients with advanced hematologic malignancies harbouring IDH2 mutations (Wong et al., 2017).